Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jacques Neefjes is active.

Publication


Featured researches published by Jacques Neefjes.


Nature Reviews Immunology | 2011

Towards a systems understanding of MHC class I and MHC class II antigen presentation

Jacques Neefjes; Marlieke L.M. Jongsma; Petra Paul; Oddmund Bakke

The molecular details of antigen processing and presentation by MHC class I and class II molecules have been studied extensively for almost three decades. Although the basic principles of these processes were laid out approximately 10 years ago, the recent years have revealed many details and provided new insights into their control and specificity. MHC molecules use various biochemical reactions to achieve successful presentation of antigenic fragments to the immune system. Here we present a timely evaluation of the biology of antigen presentation and a survey of issues that are considered unresolved. The continuing flow of new details into our understanding of the biology of MHC class I and class II antigen presentation builds a system involving several cell biological processes, which is discussed in this Review.


Journal of Experimental Medicine | 2006

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Eric Reits; James W. Hodge; Carla Herberts; Tom A. Groothuis; Mala Chakraborty; Elizabeth K. Wansley; Kevin Camphausen; Rosalie M. Luiten; Arnold H. de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A. W. Verreck; Hergen Spits; Jeffrey Schlom; Peter A. van Veelen; Jacques Neefjes

Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to γ-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.


Nature Cell Biology | 2001

From fixed to FRAP: measuring protein mobility and activity in living cells.

Eric Reits; Jacques Neefjes

Experiments with fluorescence recovery after photobleaching (FRAP) started 30 years ago to visualize the lateral mobility and dynamics of fluorescent proteins in living cells. Its popularity increased when non-invasive fluorescent tagging became possible with the green fluorescent protein (GFP). Many researchers use GFP to study the localization of fusion proteins in fixed or living cells, but the same fluorescent proteins can also be used to study protein mobility in living cells. Here we review the potential of FRAP to study protein dynamics and activity within a single living cell. These measurements can be made with most standard confocal laser-scanning microscopes equipped with photobleaching protocols.


Current Biology | 2001

The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors

Ingrid Jordens; Mar Fernandez-Borja; Marije Marsman; Simone Dusseljee; Lennert Janssen; Jero Calafat; Hans Janssen; Richard Wubbolts; Jacques Neefjes

Many intracellular compartments, including MHC class II-containing lysosomes, melanosomes, and phagosomes, move along microtubules in a bidirectional manner and in a stop-and-go fashion due to the alternating activities of a plus-end directed kinesin motor and a minus-end directed dynein-dynactin motor. It is largely unclear how motor proteins are targeted specifically to different compartments. Rab GTPases recruit and/or activate several proteins involved in membrane fusion and vesicular transport. They associate with specific compartments after activation, which makes Rab GTPases ideal candidates for controlling motor protein binding to specific membranes. We and others [7] have identified a protein, called RILP (for Rab7-interacting lysosomal protein), that interacts with active Rab7 on late endosomes and lysosomes. Here we show that RILP prevents further cycling of Rab7. RILP expression induces the recruitment of functional dynein-dynactin motor complexes to Rab7-containing late endosomes and lysosomes. Consequently, these compartments are transported by these motors toward the minus end of microtubules, effectively inhibiting their transport toward the cell periphery. This signaling cascade may be responsible for timed and selective dynein motor recruitment onto late endosomes and lysosomes.


Nature | 2000

The major substrates for TAP in vivo are derived from newly synthesized proteins.

Eric Reits; Jan C. Vos; Monique Grommé; Jacques Neefjes

The transporter associated with antigen processing (TAP) is a member of the family of ABC transporters that translocate a large variety of substrates across membranes. TAP transports peptides from the cytosol into the endoplasmic reticulum for binding to MHC class I molecules and for subsequent presentation to the immune system. Here we follow the lateral mobility of TAP in living cells. TAPs mobility increases when it is inactive and decreases when it translocates peptides. Because TAP activity is dependent on substrate, the mobility of TAP is used to monitor the intracellular peptide content in vivo. Comparison of the diffusion rates in peptide-free and peptide-saturated cells indicates that normally about one-third of all TAP molecules actively translocate peptides. However, during an acute influenza infection TAP becomes fully employed owing to the production and degradation of viral proteins. Furthermore, TAP activity depends on continuing protein translation. This implies that MHC class I molecules mainly sample peptides that originate from newly synthesized proteins, to ensure rapid presentation to the immune system.


Cell | 1990

The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route

Jacques Neefjes; Volker Stollorz; Peter J. Peters; Hans J. Geuze; Hiddle L. Ploegh

We studied the intracellular traffic and subcellular distribution of MHC class I and class II antigens in comparison with a recycling surface glycoprotein, the transferrin receptor (Tfr), in the human lymphoblastoid cell line JY. No internalization was detectable for class I molecules. Class II molecules were internalized but did not recycle. In contrast, Tfr was found to internalize and recycle. The biosynthetic pathway of class II molecules differ from that of class I molecules in that it shows a delay (1-3 hr) in transport from trans-Golgi to cell surface: here it intersects the endocytic route. Immunoelectron microscopy using anti-MHC antibodies revealed the existence of vesicular structures that were intensely labeled for class II molecules. It is proposed that at this site combination of class II molecules with processed antigen could occur.


Nature | 2005

Cross-presentation by intercellular peptide transfer through gap junctions

Joost Neijssen; Carla Herberts; Jan Wouter Drijfhout; Eric Reits; Lennert Janssen; Jacques Neefjes

Major histocompatibility complex (MHC) class I molecules present peptides that are derived from endogenous proteins. These antigens can also be transferred to professional antigen-presenting cells in a process called cross-presentation, which precedes initiation of a proper T-cell response; but exactly how they do this is unclear. We tested whether peptides can be transferred directly from the cytoplasm of one cell into the cytoplasm of its neighbour through gap junctions. Here we show that peptides with a relative molecular mass of up to ∼1,800 diffuse intercellularly through gap junctions unless a three-dimensional structure is imposed. This intercellular peptide transfer causes cytotoxic T-cell recognition of adjacent, innocent bystander cells as well as activated monocytes. Gap-junction-mediated peptide transfer is restricted to a few coupling cells owing to the high cytosolic peptidase activity. We present a mechanism of antigen acquisition for cross-presentation that couples the antigen presentation system of two adjacent cells and is lost in most tumours: gap-junction-mediated intercellular peptide coupling for presentation by bystander MHC class I molecules and transfer to professional antigen presenting cells for cross-priming.


Cell | 1990

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro

Ton N. M. Schumacher; Marie-Therese Heemels; Jacques Neefjes; W. Martin Kast; Cees Melief; Hidde L. Ploegh

MHC class I molecules devoid of peptide are expressed on the cell surface of the mouse mutant lymphoma cell line RMA-S upon culture at reduced temperature. Empty class I molecules are thermolabile at the cell surface and in detergent lysates, but can be stabilized by the addition of presentable peptide; peptide binding appears to be a rapid process. Furthermore, class I molecules on the surface of RMA-S (H-2b haplotype) cells cultured at 26 degrees C can efficiently and specifically bind iodinated peptide presented by H-2Kb. Binding of iodinated peptide is also observed at a lower level for nonmutant cells (RMA) cultured at 26 degrees C. These experiments underscore the role for peptide in maintenance of the structure of class I molecules and, more importantly, provide two assay systems to study the interactions of peptides with MHC class I molecules independent of the availability of T cells that recognize a particular peptide-MHC class I complex.


Nature Reviews Immunology | 2003

Making sense of mass destruction: quantitating MHC class I antigen presentation.

Jonathan W. Yewdell; Eric Reits; Jacques Neefjes

MHC class I molecules bind short peptides and present them to CD8+ T cells. Contrary to textbook descriptions, the generation of MHC class-I-associated peptides from endogenous proteins is a highly dynamic and remarkably inefficient process. Here, we describe recent experiments that show how nascent and mature proteins are degraded into peptides that are trimmed, transported and trimmed again to enable presentation of a small portion of the generated peptides. By linking the failure rate of protein synthesis with antigen presentation, a rapid T-cell response is ensured, which is crucial in combating viral infections. Presentation on MHC class I molecules is achieved by less than 0.1% of the specific peptides that have survived intracellular destruction. The other peptides are converted into free amino acids that are used for recycling into new proteins.


Cell | 1993

Mice lacking the MHC class II-associated invariant chain

Stéphane Viville; Jacques Neefjes; Vincent Lotteau; Andrée Dierich; Marianne LeMeur; Hidde L. Ploegh; Christophe Benoist; Diane Mathis

The invariant chain (li) has aroused much interest because of its close association with major histocompatibility complex (MHC) class II molecules. Various functions have been proposed for it; several of these have received experimental support, but most have not been definitively proven, owing largely to uncertainties inherent in the experimental systems employed. We have now generated a line of mice devoid of the invariant chain by introducing a drastic mutation into the li gene. Cells from mutant animals show aberrant transport of MHC class II molecules, resulting in reduced levels of class II complexes at the surface, and these do not have the typical compact conformation indicative of tight peptide binding. Consequently, mutant cells present protein antigens very poorly and mutant mice are deficient in producing and at negatively selecting CD4+ T cells.

Collaboration


Dive into the Jacques Neefjes's collaboration.

Top Co-Authors

Avatar

Hans Janssen

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Lennert Janssen

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Hidde L. Ploegh

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Eric Reits

University of Amsterdam

View shared research outputs
Top Co-Authors

Avatar

Huib Ovaa

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Desiree Verwoerd

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Alexander Griekspoor

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Ilana Berlin

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Tom A. Groothuis

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Wilbert Zwart

Netherlands Cancer Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge